Form 6-K Midatech Pharma Plc For: Jun 10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month of June 2022
Commission File Number 001-37652
Midatech Pharma PLC
(Translation of registrant’s name into English)
1 Caspian Point,
Caspian Way
Cardiff, CF10 4DQ, United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
This Report on Form 6-K, including Exhibits 99.1 and 99.2, is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-233901).
SUBMITTED HEREWITH
Attached to the Registrant’s Form 6-K filing for the month of June 2022, and incorporated by reference herein, is:
Exhibit No. | Description | |
99.1 | Press release dated June 10, 2022 entitled “Retirement of Chairman and Proposed Appointment of New Chairman” | |
99.2 | Press release dated June 10, 2022 entitled “An Update to MTX110 Study in Pediatric Patients with DIPG to be Presented at The International Symposium on Pediatric Neuro-Oncology, Hamburg, Germany (ISPNO 2022)” |
The information in the attached Exhibits 99.1 and 99.2 are being
furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference
in any filing made by the Registrant under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth
herein or as shall be expressly set forth by specific reference in such a filing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Midatech Pharma PLC | ||
Date: June 10, 2022 | By: | /s/ Stephen Stamp |
Stephen Stamp | ||
Chief Executive Officer and Chief Financial Officer |
Exhibit Index
Exhibit No. | Description | |
99.1 |
Press release, dated June 10, 2022 entitled
“Retirement of Chairman and Proposed Appointment of New Chairman” | |
99.2 |
Press release, dated June 10, 2022 entitled
“An Update to MTX110 Study in Pediatric Patients with DIPG to be Presented at The International Symposium on Pediatric Neuro-Oncology, Hamburg, Germany (ISPNO 2022)” |
Exhibit 99.1
10 June 2022
Midatech Pharma PLC
(“Midatech” or the “Company”)
Retirement of Chairman and Proposed Appointment of New Chairman
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, announces that Rolf Stahel, Chairman and non-executive director, intends to retire after the Company’s Annual General Meeting on 20 June 2022 (“AGM”). It is expected that Dr. Stephen Parker will be appointed as non-executive Chairman of the Board, following the AGM.
Stephen Parker has over 30 years’ experience in leadership roles both in the healthcare industry and in advisory roles. Currently, he is Chairman of Sareum Holdings plc (AIM: SAR) and Drishti Discoveries Ltd, a Non-Executive Director of MGC Pharmaceuticals Ltd (LON: MXC) and an Executive Director of sp2 Consulting Limited. Previously, Stephen held a number of executive and board positions at various public and private biotech companies and senior roles at leading investment banks. Stephen has an MBA from City University and a D.Phil. in biochemistry from Oxford University.
Commenting, Stephen Stamp, CEO and CFO of Midatech, said: “On behalf of all stakeholders I would like to thank Rolf for his contribution to Midatech over the last seven years and, from a personal perspective, for his leadership and counsel during my tenure over the last two years. We wish him well in his much deserved retirement. I should also like to welcome Stephen to the Board. Stephen’s broad experience both as an executive in, and senior adviser to, the industry will be invaluable to Midatech in the next stage of the Company’s evolution. I am very much looking forward to working with Stephen.”
Commenting, Stephen Parker, said: “It is a great pleasure to be proposed as a director, and Chairman, of Midatech, whose technology base I have long admired. It is a particular privilege to be asked to succeed Rolf Stahel and I join Stephen in thanking Rolf for his leadership to date. I look forward to working with the Midatech Board and team.”
Commenting, Rolf Stahel, added: “I am handing over the Chairman function to Stephen Parker whose proposed appointment has the unanimous support from the directors of Midatech. I have full confidence that Stephen Parker and Stephen Stamp, together with the other non-executive directors will form a powerful team leading Midatech to its promising future. I would like to thank all stakeholders for the support I have received over the last seven years.”
For more information, please contact:
Midatech Pharma PLC |
Stephen Stamp, CEO, CFO |
Tel: +44 (0)29 20480 180 |
www.midatechpharma.com |
Strand Hanson Limited (Nominated and Financial Adviser) |
James Dance / Matthew Chandler / Rob Patrick |
Tel: +44 (0)20 7409 3494 |
Turner Pope Investments (TPI) Limited (Joint Broker) |
Andrew Thacker / James Pope Tel: +44 (0)20 3657 0050 |
IFC Advisory Limited (Financial PR and UK Investor Relations) |
Tim Metcalfe / Graham Herring |
Tel: +44 (0)20 3934 6630 |
Email: [email protected] |
Edison Group (US Investor Relations) |
Alyssa Factor |
Tel: +1 (860) 573 9637 |
Email: [email protected] |
About Midatech Pharma PLC
Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The Company combines approved and development medications with its proprietary and innovative drug delivery technologies, to provide compelling products that have the potential to powerfully impact the lives of patients.
The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company’s technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:
· | Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months). |
· | MidaSolve™ platform: an innovative nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours. |
· | MidaCore™ platform: a leading-edge nanotechnology used for targeting medications to sites of disease. |
The platform nature of the technologies offers the potential to develop multiple drug assets rather than being reliant on a limited number of programmes. Midatech’s technologies are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. Midatech's headquarters and R&D facility is in Cardiff, UK. For more information please visit www.midatechpharma.com
Exhibit 99.2
10 June 2022
Midatech Pharma PLC
(“Midatech” or the “Company”)
An Update to MTX110 Study in Pediatric Patients with DIPG to be Presented
at
The International Symposium on Pediatric Neuro-Oncology, Hamburg, Germany (ISPNO 2022)
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that investigators from Columbia University Irving Medical Center and NewYork-Presbyterian will present interim results from their ongoing Phase 1 study on Midatech’s MTX110 in Diffuse Intrinsic Pontine Glioma (“DIPG”) at The International Symposium on Pediatric Neuro-Oncology (“ISPNO 2022”) that will take place on 12-15 June 2022 in Hamburg, Germany. The presentation is titled: “A Phase I study examining the feasibility of intermittent convection-enhanced delivery (CED) of MTX110 for the treatment of children with newly diagnosed diffuse midline gliomas.”
The presentation will take place on 13 June 2022 in the neurosurgery section of the conference, at 10.30 am CEST. The investigators will show first data on seven out of the ten planned patients on the safety of MTX110 (a water-soluble formulation of panobimostat) in patients with DIPG. This study uses an implantable pump and catheter system that allows for continuous intratumoral administration of the study drug without the need for repeated surgery. The study continues its recruitment.
The agenda of the meeting may be found here:
https://www.ispno2022.de/program/scientific-program/
Commenting, Dmitry Zamoryakhin, CSO of Midatech, said: “The presentation by the investigators from Columbia University Irving Medical Center and NewYork-Presbyterian will show first data on the safety of MTX110 use in patients with DIPG. This study uses an implantable pump and catheter system that allows for continuous intratumoral administration of the study drug without the need for repeated surgery. The same device is going to be used in another study of MTX110 in adult patients with recurrent glioblastoma, which we aim to begin in the second half of 2022.”
About MTX110
MTX110 is a water-soluble form of panobinostat free base, achieved through complexation with hydroxypropyl-β-cyclodextrin (HPBCD), that enables convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour. Panobinostat is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor). The currently available oral formulation of panobinostat lactate (Farydak®) is not suitable for treatment of brain cancers owing to poor blood-brain barrier penetration and inadequate brain drug concentrations. Based on favourable translational science data, MTX110 is being evaluated clinically as a treatment for DIPG (NCT03566199, NCT04264143) and recurrent medulloblastoma (NCT04315064), and preclinically for treatment of glioblastoma (SNO 2020 Abstract TMOD-27). MTX110 is delivered directly into and around the patient's tumour via a catheter system (e.g. CED or fourth ventricle infusions) to bypass the blood-brain barrier. This technique exposes the tumour to very high drug concentrations while simultaneously minimising systemic drug levels and the potential for toxicity and other side effects. Panobinostat has demonstrated high potency against DIPG tumour cells in in vitro and in vivo models, and in a key study it was the most promising of 83 anticancer agents tested in 14 patient-derived DIPG cell lines (Grasso et al, 2015. Nature Medicine 21(6), 555-559).
For more information, please contact:
Midatech Pharma PLC |
Dmitry Zamoryakhin, CSO |
Tel: +44 (0)29 20480 180 |
www.midatechpharma.com |
Strand Hanson Limited (Nominated and Financial Adviser) |
James Dance / Matthew Chandler / Rob Patrick |
Tel: +44 (0)20 7409 3494 |
Turner Pope Investments (TPI) Limited (Joint Broker) |
Andrew Thacker (Corporate Broking) Tel: +44 (0)20 3657 0050 |
IFC Advisory Limited (Financial PR and UK Investor Relations) |
Tim Metcalfe / Graham Herring |
Tel: +44 (0)20 3934 6630 |
Email: [email protected] |
Edison Group (US Investor Relations) |
Alyssa Factor |
Tel: +1 (860) 573 9637 |
Email: [email protected] |
About Midatech Pharma PLC
Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The Company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.
The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company’s technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:
· | Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months). |
· | MidaSolve™ platform: an innovative nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours. |
· | MidaCore™ platform: a leading-edge nanotechnology used for targeting medications to sites of disease. |
The platform nature of the technologies offers the potential to develop multiple drug assets rather than being reliant on a limited number of programmes. Midatech’s technologies are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. Midatech's headquarters and R&D facility is in Cardiff, UK. For more information please visit www.midatechpharma.com
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States Private Securities Litigation Reform Act. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.
Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- InventHelp Inventor Develops Oiler Tray for Fire Sprinkler Fitters & Plumbers (TPL-377)
- Pizza Nova opens fourth location in Oakville
- Computational Biology Pioneer Katie Pollard Elected as AAAS Fellow
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!